AACR 2022 Poster 4221

Characterization of OVA-Expressing Immunogenic Syngeneic Tumor Models for Immune Checkpoint Inhibitor Evaluation

Chenpan Nie, Jun Zhou, Annie An, Jia Zheng, Yi Zhang, Henry Q.X. Li, Jessie J.J. Wang
Crown Bioscience Inc., 16550 West Bernardo Drive, Building 5, Suite 525, San Diego, CA 92127, USA

Syngeneic mouse tumor models are widely used as preclinical models for immuno-oncology (I/O) research. However, their response to immune checkpoint inhibitors (ICIs) in vivo is limited, despite the increase in tumor infiltrating lymphocytes (TILs), which is potentially due to low intrinsic immunogenicity.

Expression of chicken ovalbumin (OVA) engineered into syngeneic tumors has previously been shown to render the cells more immunogenic and increases the response to ICIs such as anti-PD-1. In this study we investigated the potential to increase the response to ICIs through OVA expression and characterized the model for TILs and T cell-mediated immunity compared with parent cell line.

Download this Poster to Discover:

• Improved anti-PD-1 response observed in OVA models on average with a variation in response across models
  
  
• ACT assays confirmed the response was OVA specific
  
  
• EMT-6 OVA inhibited the tumor growth well in the re-challenge study
  
  
• CD4 and CD8 depletion was confirmed by FACS, which resulted in tumor re-growth post depletion

Download the Poster Now!